Number of Employees: Approximately 700
Marlboro, L&M, Chesterfield, SG, Português, IQOS, HEETS
Welcome to Tabaqueira, Philip Morris International's affiliate in Portugal. We are the largest tobacco company in Portugal and one of the largest in the world.
The first time that Philip Morris International established a subsidiary in Portugal was in the early 1980s and this quickly evolved into a partnership with Tabaqueira, which was state-owned at the time, to begin to manufacture Marlboro brand cigarettes under licence. The relationship between the two companies continued to improve and in 1996, Philip Morris International was the main company in a consortium that bought Tabaqueira.
Tabaqueira’s factory, in Sintra Municipality is one Philip Morris International's largest production facilities in the European Union region and it is also one of the country's five main export companies, sending its output to more than 30 countries.
We are proud of the talent of our employees and in our leading portfolio of national and international brands that we produce and sell in Portugal, including the most famous and successful cigarettes in the world, Marlboro, as well at the top selling Portuguese brand, SG.
Tabaqueira is committed to contributing to the community where it operates and where many of its employees live. There are currently four main areas of intervention under the scope of our contribution policies: Access to Education, Disaster Relief and Preparedness, Economic Opportunities and Empowering Women.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and cause addiction. There is endless medical and scientific evidence that smoking causes lung cancer, heart diseases and other serious illnesses. Smokers are much more likely of contract one of these diseases than non-smokers. Smoking causes addiction and can be extremely difficult to quit. Philip Morris International shares the opinion of the main medical and scientific organisations in the world about these matters.
Exposure to second-hand smoke
Public health authorities have concluded that exposure to other people's smoke, from cigarettes, causes serious illnesses in non-smokers, including lung cancer and heart diseases. We believe that the public health conclusions about second-hand smoke are enough to support smoking restrictions in public places.
A new generation of products with reduced risk potential
Smoking causes many serious diseases and, although there has been a down-turn in the prevalence of tobacco consumption in many countries, it is estimated that there will be more than a billion smokers in the world by 2020. Providing alternative, innovative products with a significantly lower risk potential than cigarettes and that arouse interest in current adult smokers, is one of PMI's major objectives.
That is why, apart from manufacturing and selling cigarettes, we are striving to develop and commercialize Reduced Risk Products ("RRP"). RRP is how PMI refers to products with the potential to reduce individual risk and population harm in comparison to the use of conventional cigarettes. PMI’s RRPs are in various stages of development and commercialization and PMI is conducting extensive and rigorous scientific studies in order to determine whether it can support claims for such products of reduced exposure to harmful and potentially harmful constituents in smoke, and ultimately claims of reduced disease risk, when compared to conventional cigarettes. Using multidisciplinary skills to develop the product, modern facilities and unparalleled scientific substantiation, PMI intends to offer a portfolio of RRP that corresponds to a wide range of adult smoker preferences and the strict regulatory requirements.
Philip Morris International supports the approval of effective, sound legislation for tobacco products based on the principles of harm reduction.
In order to be effective, tobacco legislation must be substantiated and aim to improve public health. It must cover all tobacco products and tobacco manufacturers and bear in mind the perspectives of all legitimate stakeholders, including public health authorities, tax authorities, tobacco manufacturers and other legitimate participants in the tobacco distribution chain, tobacco farmers and consumers. Tobacco legislation must avoid inducing adverse consequences that harm the public health objectives, such as higher demand for cigarettes and other tobacco products on illicit sales circuits.
Although we support wide-ranging legislation, we do not support legislative provisions that ban adult smokers from buying and consuming tobacco products and that impose unnecessary constraints on the workings of the legitimate tobacco market. In this regard, we are against measures such as unbranded packaging, prohibition of display at sales points, total prohibition on marketing to adult consumers and prohibitions on the use of all ingredients in the tobacco products and other measures destined to standardise the tobacco products or the packages, likewise, we also oppose the proposals that prevent the development, marketing and sale of products that have been proven to reduce the health risks caused by consuming tobacco.
This kind of legislative measures are prohibitive policies that severely restrict or even eliminate the possibility of tobacco companies competing against each other. The adverse consequences in terms of public health, often poorly understood or ignored, consist of opening the doors to the illicit cigarette market - a market where the operators do not comply with current legislation, including laws on minimum age, and which is a source of funding for organised crime.